Table 2 General characteristics of child-relevant reviews, overall and for the five CRGs containing the largest number of child-relevant reviews
|  | Overall n = 1293 | Airways n = 148 | Cystic Fibrosis and Genetic Diseases n = 102 | Acute Respiratory Infections n = 100 | Developmental, Psychological, and Learning Problems n = 86 | Infectious Diseases n = 79 |
|---|---|---|---|---|---|---|
Publication Characteristics | ||||||
 Year protocol published (median) | 2004 | 2001 | 2003 | 2004 | 2006 | 2003 |
 Year review published (median) | 2007 | 2003 | 2006 | 2007 | 2008 | 2006 |
 Number of years between publication of protocol and review (median [IQR]) | 2 (0,4) | 2 (1,2) | 1 (1,2) | 2 (2,3) | 1.5 (1,2) | 2 (1,3) |
 Year last assessed as up-to-date (median) | 2010 | 2009 | 2011 | 2011 | 2010 | 2009 |
Country Classification of corresponding author: income level (World Bank: http://www.worldbank.org/), n (% total) | ||||||
 High income | 1066 (83.5) | 140 (95.2) | 87 (87.9) | 68 (68.7) | 74 (86.1) | 45 (59.2) |
 Upper middle income | 142 (11.1) | 5 (3.4) | 7 (7.1) | 20 (20.2) | 9 (10.5) | 10 (13.2) |
 Lower middle income | 62 (4.9) | 2 (1.4) | 5 (5.1) | 11 (11.1) | 3 (3.5) | 18 (23.7) |
 Low income | 6 (0.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (4.0) |
Nature of intervention: classification 1, n (% total) | ||||||
 Pharmacological | 666 (51.8) | 107 (72.3) | 73 (74.5) | 61 (61.0) | 27 (31.4) | 39 (49.4) |
 Non-pharmacological | 466 (36.2) | 37 (25.0) | 22 (22.5) | 24 (24.0) | 57 (66.3) | 28 (35.4) |
 Both pharmacological and non-pharmacological | 155 (12.0) | 4 (2.7) | 3 (3.1) | 15 (15.0) | 2 (2.3) | 12 (15.2) |
Nature of intervention: classification 2, n (% total) | ||||||
 Drug | 575 (44.5) | 98 (66.2) | 58 (56.9) | 49 (49.0) | 14 (16.3) | 38 (48.1) |
 Surgical | 53 (4.1) | 2 (1.4) | 5 (4.9) | 0 (0.0) | 2 (2.3) | 2 (2.5) |
 Behavioural/educational/psychological | 169 (13.1) | 15 (10.1) | 7 (6.9) | 4 (4.0) | 43 (50.0) | 3 (3.8) |
 Device | 96 (7.4) | 13 (8.8) | 5 (4.9) | 2 (2.0) | 4 (4.7) | 2 (2.5) |
 Natural health product | 120 (9.3) | 7 (4.7) | 3 (2.9) | 22 (22.0) | 15 (17.4) | 5 (6.3) |
 Vaccine | 37 (2.9) | 4 (2.7) | 4 (3.9) | 8 (8.0) | 0 (0.0) | 12 (15.2) |
 Non-surgical clinical practice or procedure | 207 (16.0) | 6 (4.1) | 20 (19.6) | 13 (13.0) | 7 (8.1) | 14 (17.7) |
 Policy or legislation | 36 (2.8) | 3 (2.0) | 0 (0.0) | 2 (2.0) | 1 (1.2) | 3 (3.8) |
External source of funding, n (% total) | ||||||
 Not stated | 262 (20.3) | 18 (12.2) | 57 (55.9) | 13 (13.0) | 13 (15.1) | 5 (6.3) |
 No | 331 (25.6) | 26 (17.6) | 17 (16.7) | 34 (34.0) | 15 (17.4) | 4 (5.1) |
 Yes | 700 (54.1) | 104 (70.3) | 28 (27.5) | 53 (53.0) | 58 (67.4) | 70 (88.6) |
 Cochrane | 142 (11.0) | 19 (12.8) | 3 (2.9) | 12 (12.0) | 10 (11.6) | 7 (8.9) |
 Academic | 83 (6.4) | 1 (0.7) | 3 (2.9) | 11 (11.0) | 4 (4.7) | 6 (7.6) |
 Government | 461 (35.7) | 79 (53.4) | 14 (13.7) | 26 (26.0) | 33 (38.4) | 62 (78.5) |
 Industry | 7 (0.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (1.2) | 1 (1.3) |
 Non-profit organization | 235 (18.2) | 43 (29.1) | 15 (14.7) | 12 (12.0) | 24 (27.9) | 10 (12.7) |
 Other | 21 (1.6) | 2 (1.4) | 0 (0.0) | 2 (2.0) | 1 (1.2) | 0 (0.0) |